Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
z1sfMsXAEq5C7FFd
Listen
